MedTrace Logo

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

NCT04960579 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 275

Last updated 2026-04-24

No results posted yet for this study

Summary

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

Conditions

Interventions

BIOLOGICAL

P-BCMA-ALLO1 CAR-T cells

Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy

DRUG

Rimiducid

Safety switch activator

DRUG

Methotrexate

Anti-metabolite

Sponsors & Collaborators

  • Roche-Genentech

    collaborator INDUSTRY

  • Poseida Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Maika Onishi, M.D. · Senior Medical Director

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-05
Primary Completion
2029-03-31
Completion
2042-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04960579 on ClinicalTrials.gov